Background In treatment-resistant depression, commonly defined as a lack of response to
two or more consecutive treatments during the current depressive episode, the percentage …

Objectives: To provide advice and guidance regarding the management of mood disorders,
derived from scientific evidence and supplemented by expert clinical consensus to formulate …

Major depressive disorder is an often chronic and recurring illness. Left untreated, major
depressive disorder may result in progressive alterations in brain morphometry and circuit …

Objective: This article presents the case that a more rapid, individualized approach to
treating major depressive disorder (MDD) may increase the likelihood of achieving full …

Objective: To evaluate the efficacy and safety of zuranolone, an investigational neuroactive
steroid and GABA A receptor positive allosteric modulator, in major depressive disorder …

Background Ketamine is reported to have rapid antidepressant effects; however, there is
limited understanding of the time-course of ketamine effects beyond a single infusion. A …

Objectives. This 2013 update of the practice guidelines for the biological treatment of
unipolar depressive disorders was developed by an international Task Force of the World …

1-[2-(2, 4-Dimethylphenyl-sulfanyl)-phenyl]-piperazine (Lu AA21004) is a human (h)
serotonin (5-HT) 3A receptor antagonist (Ki= 3.7 nM), h5-HT7 receptor antagonist (K i= 19 …

Objective The problem of identifying, in advance, the most effective treatment agent for
various psychiatric conditions remains an elusive goal. To address this challenge, we …

Thiazolidinediones have shown antidepressant effect in animal studies, as well as in some
uncontrolled studies evaluating human subjects with concurrent major depressive disorder …